CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy
Key claim: A Phase 1/2a open-label study is evaluating intramuscular AAV9-follistatin gene therapy alone or combined with a VEGF-encoding plasmid for safety and preliminary effects on skeletal muscle mass and performance in age-related muscle loss.
Abstract
This Phase 1/2a, open-label, non-randomized study is designed to evaluate the safety and tolerability of intramuscular AAV9-Follistatin gene therapy administered either as monotherapy or in combination with a VEGF-encoding plasmid. Secondary objectives include the assessment of preliminary signals of biological and functional activity, including changes in skeletal muscle mass and performance.
Why this matters
This is one of the first human gene-therapy trials framed explicitly around age-related muscle loss rather than a rare monogenic myopathy, and it pairs a myostatin-pathway hit (AAV9-follistatin) with a vascular co-therapy (VEGF plasmid) — a design biohacker communities have speculated about but never had clinical data on. As a Phase 1/2a open-label study it establishes a trend signal and a safety-first data point, not efficacy, which matters because follistatin is already circulating in the peptide-injection underground where any ‘gene therapy works’ headline will be over-read.